Pharmacological Mechanisms in Alzheimer's Therapeutics
Springer-Verlag New York Inc.
978-1-4419-2446-9 (ISBN)
This book will be of value to a wide audience interested in cellular and molecular mechanisms leading to the pathology of Alzheimer’s disease and on the multiple, possible, therapeutic opportunities ahead of us.
Alzheimer’s disease is a serious health concern in developed countries where the population is progressively aging. At the personal level the diagnosis of the disease represents a devastating scenario for both the sufferer and care givers. In recent years medications have been developed that mitigate somewhat the symptoms and delay, for a while, the progression of the disease. It is expected that in the coming years new medications will be developed that are capable of halting the chain of pathological events and symptoms of the disease. This book covers a wide range of the pharmacological mechanism underlying present and potential new therapies. The recent extraordinary advances in our understanding of the cell and molecular biology of Alzheimer’s disease allows for an optimistic forecast of innovative therapies.
This book will be of value to a wide audience interested in cellular and molecular mechanisms leading to the pathology of Alzheimer’s disease and on the multiple, possible, therapeutic opportunities ahead of us. The field of research is enormous and therefore therapeutic targets that have been selected for this volume seem the most hopeful and for which there is a solid rationale. There are a number of emerging therapeutic targets, such as the inactivation/removal of Aß peptides, amongst others, which might have potential applications if specific leading compounds were to be identified.
Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets.- Trial Designs and Outcomes to Monitor Novel Therapeutics in Alzheimer's Disease.- The Pharmacological Treatment of Alzheimer's Disease with Cholinesterase Inhibitors and Memantine.- M1 Muscarinic Agonists: A Comprehensive Therapy Against Major Hallmarks of Alzheimer's Disease.- Cholinergic Neurodegeneration in Alzheimer's Disease: Basis for Nerve Growth Factor Therapy.- The Rationale for Glutamatergic Therapy in Alzheimer's Disease.- Secretases as Pharmacological Targets in Alzheimer's Disease.- ?-Secretase as a Target for Alzheimer's Disease.- The Rationale for an Immunological Approach to Alzheimer's Therapeutics.- Neuroinflammation, Alzheimer Disease, and Other Aging Disorders.- Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Derived A?42-Lowering Molecules for Treatment and Prevention of Alzheimer's Disease (AD).- The Potential Application of Antioxidant Agents in Alzheimer Disease Therapeutics.- Apolipoprotein E: A Potent Gene-Based Therapeutic Target for the Treatment of Sporadic Alzheimer's Disease.- Tau Pathology as a Target in Alzheimer's Therapeutics.- Design of Inhibitors of Amyloid-? Misfolding and Aggregation for Alzheimer's Therapy.- Potential Applications of Glycosaminoglycan-Related Compounds in Alzheimer's Disease.- Multifunctional Neuroprotective Drugs for the Treatment of Alzheimer's Disease.- Interpreting Clinical Studies of Putative Therapeutics for Alzheimer's Disease: The Case of Statins and NSAIDs.
| Zusatzinfo | 35 Illustrations, black and white; XX, 324 p. 35 illus. |
|---|---|
| Verlagsort | New York, NY |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Geriatrie |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Neurologie | |
| Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie | |
| Medizin / Pharmazie ► Pharmazie | |
| ISBN-10 | 1-4419-2446-9 / 1441924469 |
| ISBN-13 | 978-1-4419-2446-9 / 9781441924469 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
